None
SEDAR Interim Financial Statements
LOVE · Price
[
{
"companyName": "CANNARA BIOTECH INC.",
"reportingPeriodEnd": "2026-02-28",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cash": 21902387,
"accountsReceivable": 12474114,
"biologicalAssets": 5514554,
"inventory": 48637424,
"prepaidExpensesAndOtherAssets": 2600898,
"totalCurrentAssets": 91129377,
"deposits": 159160,
"deferredFinancingCosts": 164274,
"depositsOnPropertyPlantAndEquipment": 487748,
"propertyPlantAndEquipment": 89654794,
"rightOfUseAsset": 212918,
"totalAssets": 181808271,
"accountsPayableAndAccruedLiabilities": 11919434,
"exciseTaxPayable": 7192034,
"salesTaxPayable": 1472443,
"deferredLeaseRevenue": 72740,
"revolvingCreditFacilities": 6758000,
"currentPortionOfConvertibleDebenture": 0,
"currentPortionOfLongTermDebt": 56576,
"currentPortionOfDeferredGrantIncome": 125386,
"currentPortionOfLeaseLiabilities": 222913,
"currentPortionOfTermLoan": 1965961,
"totalCurrentLiabilities": 29785487,
"leaseLiabilities": 23936,
"convertibleDebenture": 0,
"deferredGrantIncome": 1367472,
"deferredIncomeTaxLiabilities": 5224659,
"termLoan": 25197505,
"totalLiabilities": 61599059,
"shareCapital": 104098909,
"contributedSurplus": 13229826,
"retainedEarnings": 2880477,
"totalEquity": 120209212,
"cashPerShare": 0.2305,
"workingCapitalPerShare": 0.6455
},
"incomeStatement": {
"revenueFromSaleOfGoods": 79641451,
"exciseTaxes": -24368498,
"netRevenueFromSaleOfGoods": 55272953,
"leaseRevenues": 1953226,
"otherIncome": 66438,
"totalRevenue": 57292617,
"costOfGoodsSold": 31979567,
"leaseOperatingCosts": 274620,
"grossProfitBeforeFairValueAdjustments": 25038430,
"changesInFairValueOfInventorySold": -12919868,
"unrealizedGainOnChangesInFairValueOfBiologicalAssets": 10739014,
"grossProfit": 22857576,
"generalAndAdministrative": 6376034,
"sellingMarketingAndPromotion": 5525948,
"professionalAndLegalFees": 832739,
"researchAndDevelopment": 688144,
"shareBasedCompensation": 2811556,
"depreciation": 519725,
"lossOnDisposalOfPropertyPlantAndEquipment": 122008,
"totalOperatingExpenses": 16876154,
"operatingIncome": 5981422,
"netFinanceExpense": 1120603,
"incomeBeforeIncomeTaxes": 4860819,
"incomeTaxesExpense": 2158622,
"netIncomeAndComprehensiveIncome": 2702197,
"earningsPerShareBasic": 0.03,
"earningsPerShareDiluted": 0.03,
"weightedAverageNumberOfCommonSharesBasic": 95029610,
"weightedAverageNumberOfCommonSharesDiluted": 97295876
},
"cashFlowStatement": {
"operatingActivities": {
"netIncome": 2702197,
"changesInFairValueOfInventorySold": 12919868,
"unrealizedGainOnChangesInFairValueOfBiologicalAssets": -10739014,
"depreciationOfPropertyPlantAndEquipment": 2754234,
"depreciationOfRightOfUseAssets": 136087,
"lossOnDisposalOfPropertyPlantAndEquipment": 122008,
"lossOnConvertibleDebentureExtension": 0,
"interestExpense": 937764,
"interestOnLeaseLiabilities": 16161,
"interestIncome": -166971,
"shareBasedCompensation": 2811556,
"accretionAndAmortizationOfFinancingCosts": 119720,
"incomeTaxesExpense": 2158622,
"netChangeInNonCashOperatingWorkingCapitalItems": -2862943,
"cashProvidedByOperatingActivities": 10909289
},
"investingActivities": {
"depositsOnPropertyPlantAndEquipment": -673886,
"acquisitionsOfPropertyPlantAndEquipment": -7179118,
"proceedFromDisposalOfPropertyPlantAndEquipment": 140000,
"interestReceived": 147763,
"cashUsedInInvestingActivities": -7565241
},
"financingActivities": {
"proceedFromPrivatePlacement": 6300000,
"equityTransactionCostsPaid": -42552,
"repaymentOfTermLoan": -982981,
"proceedsFromCreditFacilities": 0,
"debtFinancingIssuanceCostsPaid": -112110,
"interestPaidOnDebtInstruments": -634017,
"paymentOfInterestOnLetterOfCredit": 0,
"leasePayments": -165274,
"otherLongTermDebtPayments": -164743,
"cashProvidedByFinancingActivities": 4198323
},
"netChangeInCash": 7542371,
"cashBeginningOfPeriod": 14360016,
"cashEndOfPeriod": 21902387
},
"investmentsAndOtherAssets": [],
"shareStructure": {
"authorizedShares": "unlimited",
"issuedShares": 98782148,
"classesOfShares": ["common shares"],
"warrants": [],
"options": [
{
"number": 83500,
"exercisePrice": 1.8,
"expiryDate": "2027-02-28"
},
{
"number": 590000,
"exercisePrice": 1.8,
"expiryDate": "2028-02-29"
},
{
"number": 702500,
"exercisePrice": 1.8,
"expiryDate": "2029-02-28"
},
{
"number": 2100000,
"exercisePrice": 1.4,
"expiryDate": "2030-02-28"
},
{
"number": 677500,
"exercisePrice": 1.5,
"expiryDate": "2031-02-28"
},
{
"number": 4471500,
"exercisePrice": 1.4,
"expiryDate": "2032-02-29"
}
],
"rightsConvertibleInstruments": null
},
"managementCompensation": {
"currency": "CAD",
"periods": {
"threeMonth": {
"salariesAndBenefits": 300000,
"shareBasedCompensation": 868340,
"boardOfDirectorsFees": 43750
},
"sixMonth": {
"salariesAndBenefits": 600000,
"shareBasedCompensation": 2264894,
"boardOfDirectorsFees": 87500
}
},
"namedIndividuals": [],
"otherRelatedPartyTransactions": [
{
"counterparty": "Related party",
"description": "Other expenses",
"amount": 8476,
"period": "sixMonth"
},
{
"counterparty": "Related party",
"description": "Acquisition of property, plant and equipment",
"amount": 246791,
"period": "sixMonth"
},
{
"counterparty": "Related party",
"description": "Interest on debt financing",
"amount": 54038,
"period": "sixMonth"
}
]
},
"subsequentEvents": [
{
"eventDate": null,
"description": "Granted 10,000 stock options at an exercise price of $1.87 to employees, vesting in one year and expiring after seven years.",
"impactValue": null
},
{
"eventDate": null,
"description": "Extended all tranches of the revolving credit facilities for an additional 90-day term at a weighted average interest rate of 4.89%.",
"impactValue": null
},
{
"eventDate": null,
"description": "Drew $2 million under the $10 million capital expenditure facility for the construction of Valleyfield expansion project.",
"impactValue": 2000000
}
]
}
]
More from Cannara Biotech Inc
May 06, 2026 · 08:00